Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate

Abstract

A method of treatment for intestinal gas bloating, microscopic colitis, traveler's diarrhea and inflammatory bowel disease, said method comprising ingesting an effective quantity of a composition comprising colloidal bismuth subcitrate to eliminate gastrointestinal discomfort.

I claim: 
     
         1 . A method of treatment for intestinal gas bloating, microscopic colitis and traveler's diarrhea, said method comprising ingesting an effective quantity of a composition comprising colloidal bismuth subcitrate to eliminate gastrointestinal discomfort. 
     
     
         2 . The method according to  claim 1 , wherein the composition contains at least 125 mg of colloidal bismuth subcitrate. 
     
     
         3 . The method according to  claim 2 , wherein the composition is administered once daily. 
     
     
         4 . The method according to  claim 2 , wherein the composition is administered twice daily. 
     
     
         5 . The method according to  claim 2 , wherein the composition is administered up to six times a day. 
     
     
         6 . The method according to  claim 1 , wherein the composition contains between 125 mg and 900 mg of colloidal bismuth subcitrate. 
     
     
         7 . A topical oral dosage selected from the group consisting of chewing gums, lozenges, troches, and combinations thereof, wherein the topical oral dosage form comprises a pharmaceutically active agent effective against intestinal gas bloating, microscopic colitis and traveler's diarrhea, wherein the pharmaceutically active agent comprises colloidal bismuth subcitrate. 
     
     
         8 . The topical oral dosage of  claim 7  wherein the dosage form is a chewing gum. 
     
     
         9 . The topical oral dosage of  claim 7  wherein the dosage form is a lozenge. 
     
     
         10 . The topical oral dosage of  claim 7  wherein the dosage form is a troche. 
     
     
         11 . The topical dosage of  claim 7  wherein the topical dosage form is chewing gum. 
     
     
         12 . The topical dosage of  claim 11  wherein the chewing gum comprises between about 125 mg and about 900 mg of colloidal bismuth subcitrate. 
     
     
         13 . The method according to  claim 1 , wherein the composition contains ranitidine bismuth citrate at a dose of 400 mg, administered daily or up to three times per day. 
     
     
         14 . The method according to  claim 1 , wherein the composition contains ranitidine bismuth citrate at a dose of 800 mg, administered daily or up to three times per day. 
     
     
         15 . The method according to  claim 1 , wherein the composition further contains one or more of the following simethicone, a steroid, an anti-inflammatory, and an antibiotic.